01 December 2024 : Clinical Research
Rituximab use in Rheumatoid Arthritis: A Seven-Year Retrospective Study of 52 Patients at a Saudi Arabian Hospital
Sumayah Sulaiman Bafana1BCE, Fahidah Alenzi
2EFG*, Ibrahim Almaghlouth1AD, Eman Alqurtas 1AD, Mohammed K. Bedaiwi1ABD, Haya M. M. Almalag 3AD, Mohammed A. Omair 1ACDEF
DOI: 10.12659/MSM.946178
Med Sci Monit 2024; 30:e946178
Table 1 Demographic characteristics of patients who used rituximab.
| Characteristic | Description |
|---|---|
| Female sex (n (%)) | 44 (84.6) |
| Age (mean±SD) | 57.1±11.1 |
| Disease duration (median+IQR) | 11.5 (9.25–20) |
| Living in Riyadh (n (%)) | 35 (67.3) |
| Never smoked (n (%)) | 51 (98.1) |
| Positive rheumatoid factor (n (%)) | 2 (3.8) |
| Positive anti-cyclic citrullinated peptide (n (%)) | 2 (3.8) |
| Double positive for rheumatoid factor and anti-cyclic citrullinated peptide (n (%)) | 46 (88.46) |
| Negative for rheumatoid factor or anti-cyclic citrullinated peptide (n (%)) | 2 (3.9) |
| Body mass index (mean±SD) | 30.4±6.41) |
| Presence of comorbidities (n (%)) | 37 (71.2) |
| Number of comorbidities (n (%)) | |
| 0 | 15 (28.9) |
| 1 | 17 (32.7) |
| 2 or more | 20 (38.5) |
| Presence of interstitial lung disease (n (%)) | 3 (5.8) |
| Positive latent tuberculosis (n (%)) | 7 (13.5) |
| Previous history of active tuberculosis (n (%)) | 1 (1.9) |
| Positive hepatitis C antibodies (n (%)) | 0 |
| Positive hepatitis B anti-core antibodies (n (%)) | 4 (7.7) |
| Positive hepatitis B surface antigen (n (%)) | 0 |